Financing includes new and existing leading healthcare investors

融资包括新的和现有的领先医疗保健投资者

Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028

收益以及现有现金和现金等价物预计将把现金周转期延长至2028年

PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million, before deducting placement agent fees and estimated offering expenses.

费城，2024年5月2日（环球通讯社）——Context Therapeutics Inc。推进实体瘤药物的生物制药公司（“Context”或“公司”）（纳斯达克：CNTX）今天宣布，它已与某些新的和现有的私募投资者签订了证券购买协议，预计在扣除配售代理费和估计的发行费用之前，总收益约为1亿美元。

The private placement is expected to close on May 6, 2024, subject to the satisfaction of customary closing conditions..

预计私募将于2024年5月6日结束，但须满足常规结束条件。

The private placement is led by new investor Nextech1, with participation from new and existing investors, including Ally Bridge Group, Avidity Partners, Blackstone Multi-Asset Investing, Blue Owl Healthcare Opportunities, Deep Track Capital, Driehaus Capital Management, Great Point Partners, LLC, and other leading healthcare investors..

私募由新投资者Nextech1牵头，新投资者和现有投资者参与，包括Ally Bridge Group、Avidity Partners、Blackstone Multi Asset Investment、Blue Owl Healthcare Opportunities、Deep Track Capital、Driehaus Capital Management、Great Point Partners，LLC和其他领先的医疗保健投资者。

Pursuant to the terms of the securities purchase agreement, Context is selling an aggregate of approximately 64.5 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of $1.55 per share (or $1.549 per pre-funded warrant). Each pre-funded warrant will have an exercise price of $0.001 per share of common stock, will be immediately exercisable and will not expire.

根据《证券购买协议》的条款，Context以每股1.55美元（或每股1.549美元）的价格出售其总计约6450万股普通股（或代替其的预支认股权证）。每份预先出资的认股权证的行权价格为每股普通股0.001美元，可立即行权且不会到期。

The price per share of common stock and per pre-funded warrant represents a premium to the closing price of the Company’s common stock on May 1, 2024. Context expects that the net proceeds from the private placement, together with the Company’s existing cash and cash equivalents, will extend its cash runway through the estimated duration of the Company’s planned CTIM-76 Phase 1 clinical trial, as well as into 2028..

普通股和预支认股权证的每股价格比2024年5月1日公司普通股的收盘价溢价。Context预计，私募产生的净收益以及公司现有的现金和现金等价物将使其现金周转期延长至公司计划的CTIM-76第一阶段临床试验的预计持续时间以及2028年。

Piper Sandler is acting as sole placement agent for the private placement.

派珀·桑德勒（Piper Sandler）是此次私募的独家配售代理。

The offer and sale of the securities in the private placement and described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements.

上述私募证券的发售和出售是在不涉及公开发售的交易中进行的，这些证券尚未根据修订后的《1933年证券法》进行登记，除非根据有效的登记声明或登记要求的适用豁免，否则不得在美国重新发售或转售。

Pursuant to a registration rights agreement, Context agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the shares of common stock issued in this private placement and the shares of common stock underlying the pre-funded warrants..

根据登记权协议，Context同意向美国证券交易委员会（“SEC”）提交一份登记声明，涵盖本次私募发行的普通股股份以及预支认股权证的普通股股份的转售。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何州或其他司法管辖区的证券法注册或取得资格之前，在任何州或其他司法管辖区出售这些证券都是非法的。

1 Nextech Invest Ltd, on behalf of one or more funds managed by it.

1 Nextech Invest Ltd，代表其管理的一个或多个基金。

About Context Therapeutics®

关于Context Therapeutics®

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing medicines for solid tumors. Context’s clinical stage product candidate, CTIM-76, is a selective CLDN6 x CD3 bispecific antibody for CLDN6-positive tumors. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues.

Context Therapeutics Inc.（纳斯达克：CNTX）是一家生物制药公司，致力于开发实体瘤药物。上下文的临床阶段候选产品CTIM-76是针对CLDN6阳性肿瘤的选择性CLDN6 x CD3双特异性抗体。CLDN6是在多种实体瘤（包括卵巢，子宫内膜，睾丸和肺）中表达的紧密连接膜蛋白靶标，在健康的成人组织中不存在或低水平表达。

Context is headquartered in Philadelphia..

Context总部位于费城。

Forward-looking Statements

前瞻性声明

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements.

本新闻稿包含“前瞻性声明”，涉及1995年《私人证券诉讼改革法案》提供的安全港的重大风险和不确定性。本新闻稿中关于战略、未来运营、前景、计划和管理目标的任何陈述（历史事实陈述除外），包括“可能”、“将”、“期望”、“预期”、“展望”、“计划”、“打算”等词语，以及类似的表达（以及其他涉及未来事件、条件或情况的词语或表达）都是前瞻性陈述。

These include, without limitation, statements regarding (i) the expected gross proceeds from the private placement and intended use of net proceeds, (ii) our expectation to close the private placement on or about May 6, 2024, (iii) our expectation that the funds from the private placement, together with our existing cash and cash equivalents, will extend the Company’s cash runway through the estimated duration of the Company’s planned CTIM-76 Phase 1 clinical trial, as well as into 2028, (iv) the potential benefits, characteristics, safety and side effect profile of CTIM-76, (v) the ability of CTIM-76 to have benefits, characteristics, manufacturability, and a side effect profile that is differentiated and/or better than third party product candidates, (vi) the likelihood data will support future development of CTIM-76, and (vii) the likelihood of obtaining regulatory approval for CTIM-76.

这些包括但不限于以下方面的声明：（i）私募的预期总收益和净收益的预期用途；（ii）我们预计在2024年5月6日左右完成私募；（iii）我们预计私募的资金以及我们现有的现金和现金等价物将使公司的现金跑道延长到公司计划的CTIM-76第一阶段临床试验的估计持续时间以及2028年；（iv）CTIM-76的潜在益处、特性、安全性和副作用；（v）CTIM-76具有差异化和/或更好的益处、特性、可制造性和副作用的能力（vi）可能性数据将支持CTIM-76的未来开发，以及（vii）获得CTIM-76监管批准的可能性。

Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions,.

本版本中的前瞻性声明涉及重大风险和不确定性，可能导致实际结果与前瞻性声明中明示或暗示的结果存在重大差异，因此我们无法向您保证我们的计划、意图。